• Women's healthcare footprint: Corona Remedies launched an EU-GMP approved hormone manufacturing facility and acquired a 31% equity stake in a Gujarat-based API facility to secure supplies. The segment represents 31% of total revenue and reaches 85% of the 30,000 gynaecologists and IVF specialists across India.
• Portfolio growth rates: Chronic and sub-chronic therapies expanded at 19% over the past three years to contribute 76% of total revenue, outperforming the broader market, while acute therapies grew by 12.5%.
• Acquisitions and biosimilars: The company is executing integrations for Wokadine and Bayer's infertility portfolio in FY26, deploying a 46-person task force for IVF specialists. Additionally, it entered biosimilars with launches of Fostine R, Denosumab, and a GLP-1 product.
• Capacity and capex: Unlocking 40% capacity at the Ahmedabad facility will support an expected 15% annual revenue growth over the next 2–3 years. The company plans to spend ₹175–200 crore through internal accruals to establish a fourth manufacturing facility by FY29.